Skip to main content
. 1998 Aug 18;95(17):10067–10071. doi: 10.1073/pnas.95.17.10067

Figure 4.

Figure 4

Rejection as a consequence of anti-CTLA-4 treatment and a GM-CSF-expressing vaccine results in immunity to rechallenge. Mice were treated as in Fig. 3a. Six weeks after initial challenge with SM1, mice were rechallenged (arrow) on a separate, shaved area of the back with 2 × 105 SM1 cells. Tumor growth was monitored, and incidence is indicated in parentheses.